Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 3/20 | 0.51 |
| ▸ | AKT1 | P31749 | 7/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800730 | 0.88 | KDR (0.53) | KDRAKT1RPS6KB1SMN1; SMN2TLR7 | |
| SCHEMBL807662 | 0.86 | TSHR (0.48) | AKT1HRH4TSHRSMN1; SMN2ALOX15 | |
| SCHEMBL807296 | 0.84 | SMN1; SMN2 (0.50) | AKT1HRH4NPC1TSHRRECQL | |
| SCHEMBL30579439 | 0.84 | SMN1; SMN2 (0.50) | AKT1HRH4NPC1TSHRRECQL | |
| SCHEMBL6803221 | 0.84 | KDR (0.55) | KDRAKT1RPS6KB1SMN1; SMN2TLR7 | |
| SCHEMBL5889085 | 0.83 | SMN1; SMN2 (0.53) | AKT1HRH4NPC1TSHRRECQL | |
| SCHEMBL2075530 | 0.82 | KIT (0.48) | AKT1SMN1; SMN2TLR7 | |
| SCHEMBL6801091 | 0.82 | MAP4K4 (0.57) | KDRAKT1HRH4TLR7 | |
| SCHEMBL19004851 | 0.81 | AKT1 (0.47) | AKT1HRH4NPC1TSHRRECQL | |
| SCHEMBL30662621 | 0.80 | MKNK1 (0.46) | KDRAKT1RPS6KB1HRH4TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063720-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2004-04-01 | — | — | US | disclosed |
| US-20020137755-A1 | Tyrosine kinase inhibitors | BILODEAU MARK T (US) | 2002-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137755-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885AKT1 85/4885RPS6KB1 308/4885 |
| US-20040063720-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | KDR 5/4885AKT1 85/4885RPS6KB1 308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.